Stoke Therapeutics (STOK) Net Income Growth (5y) (2023 - 2026)

Stoke Therapeutics (STOK) Net Income Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 472.89 Bn 468.10 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.12 Bn 114.87 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn
7 Belite Bio 62.68 Bn 62.68 Bn -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.47 Bn 34.46 Bn 959.66 Mn
10 Stoke Therapeutics 1.87 Bn 1.53 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -24.33%
Dec 31, 2025 -33.84%
Sep 30, 2025 -22.75%
Jun 30, 2025 -9.79%
Mar 31, 2025 64.73%
Dec 31, 2024 -7.72%
Sep 30, 2024 -25.16%
Jun 30, 2024 -26.87%
Mar 31, 2024 -35.65%
Dec 31, 2023 -104.58%
Sep 30, 2023 -52.29%